American Thyroid Association Sonographic Risk and Afirma Gene Expression Classifier Alone and in Combination for the Diagnosis of Thyroid Nodules with Bethesda Category III Cytology
The Afirma gene expression classifier (GEC) has been used to aid in the diagnosis and management of thyroid nodules having Bethesda category III fine-needle aspiration cytologic diagnosis (B3 nodules). The American Thyroid Association sonographic risk stratification system for thyroid nodules (ATA-U...
Saved in:
Published in | Thyroid (New York, N.Y.) Vol. 30; no. 11; p. 1613 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.11.2020
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The Afirma gene expression classifier (GEC) has been used to aid in the diagnosis and management of thyroid nodules having Bethesda category III fine-needle aspiration cytologic diagnosis (B3 nodules). The American Thyroid Association sonographic risk stratification system for thyroid nodules (ATA-US) may stratify B3 nodules and aid in the decision to order a molecular test. The aim of this study was to assess the association between ATA-US and GEC as well as to determine their individual and combined diagnostic performances when applied to B3 nodules.
A retrospective single-center study included B3 nodules that had undergone evaluation by GEC. Each ultrasound was reviewed by three radiologists, and nodules were classified using the 2015 ATA sonographic risk categories. Nodules were determined to be benign or malignant based on surgical pathology or minimum 11 months of follow-up. Positive predictive values (PPV) and negative predictive values (NPV) were calculated for GEC, ATA-US, and GEC across all ATA-US categories.
One hundred twenty-six B3 nodules with GEC results were included and deemed benign or malignant based on final pathology or follow-up. Prevalence of malignancy was 32%. The rate of malignancy was similar in the ATA-US high suspicion (HS) and intermediate suspicion (IS) categories at 42% and 38%, respectively; and lower in nodules with low suspicion sonography (LS) and very low suspicion sonography (VLS) at 23% and 11%, respectively. The PPV and NPV of ATA-US was calculated by designating HS or IS sonography as a "positive" test and the lower risk categories as "negative." ATA-US had a PPV of 40% and NPV of 79%. The GEC PPV was 40% and NPV was 83%. The PPV of GEC was 50% in nodules with HS or IS ATA-US and lower at 28% and 20%, respectively, in LS and VLS nodules. The NPV of GEC was 80% in HS, 77% in IS, 84% in LS, and 100% in VLS sonography categories.
In B3 nodules, ATA-US and GEC have similar diagnostic performance. The PPV of GEC varies across ATA-US categories, while the NPV remains similar. These data support the need for future prospective studies. |
---|---|
AbstractList | The Afirma gene expression classifier (GEC) has been used to aid in the diagnosis and management of thyroid nodules having Bethesda category III fine-needle aspiration cytologic diagnosis (B3 nodules). The American Thyroid Association sonographic risk stratification system for thyroid nodules (ATA-US) may stratify B3 nodules and aid in the decision to order a molecular test. The aim of this study was to assess the association between ATA-US and GEC as well as to determine their individual and combined diagnostic performances when applied to B3 nodules.
A retrospective single-center study included B3 nodules that had undergone evaluation by GEC. Each ultrasound was reviewed by three radiologists, and nodules were classified using the 2015 ATA sonographic risk categories. Nodules were determined to be benign or malignant based on surgical pathology or minimum 11 months of follow-up. Positive predictive values (PPV) and negative predictive values (NPV) were calculated for GEC, ATA-US, and GEC across all ATA-US categories.
One hundred twenty-six B3 nodules with GEC results were included and deemed benign or malignant based on final pathology or follow-up. Prevalence of malignancy was 32%. The rate of malignancy was similar in the ATA-US high suspicion (HS) and intermediate suspicion (IS) categories at 42% and 38%, respectively; and lower in nodules with low suspicion sonography (LS) and very low suspicion sonography (VLS) at 23% and 11%, respectively. The PPV and NPV of ATA-US was calculated by designating HS or IS sonography as a "positive" test and the lower risk categories as "negative." ATA-US had a PPV of 40% and NPV of 79%. The GEC PPV was 40% and NPV was 83%. The PPV of GEC was 50% in nodules with HS or IS ATA-US and lower at 28% and 20%, respectively, in LS and VLS nodules. The NPV of GEC was 80% in HS, 77% in IS, 84% in LS, and 100% in VLS sonography categories.
In B3 nodules, ATA-US and GEC have similar diagnostic performance. The PPV of GEC varies across ATA-US categories, while the NPV remains similar. These data support the need for future prospective studies. |
Author | Kargi, Atil Yilmaz Casula, Sabina Kuker, Russ Castillo, Rosa Patricia Gonzalez, Manuel Lora Thekkumkattil, Anu Valderrama, Maria Linares Arosemena, Marilyn Sidani, Charif |
Author_xml | – sequence: 1 givenname: Marilyn surname: Arosemena fullname: Arosemena, Marilyn organization: Department of Medicine, Jackson Memorial Hospital, Miami, Florida, USA – sequence: 2 givenname: Anu surname: Thekkumkattil fullname: Thekkumkattil, Anu organization: Division of Endocrinology, Jackson Memorial Hospital, University of Miami, Miami, Florida, USA – sequence: 3 givenname: Maria Linares surname: Valderrama fullname: Valderrama, Maria Linares organization: Division of Endocrinology, Jackson Memorial Hospital, University of Miami, Miami, Florida, USA – sequence: 4 givenname: Russ surname: Kuker fullname: Kuker, Russ organization: Department of Radiology, University of Miami, Miami, Florida, USA – sequence: 5 givenname: Rosa Patricia surname: Castillo fullname: Castillo, Rosa Patricia organization: Department of Radiology, University of Miami, Miami, Florida, USA – sequence: 6 givenname: Charif surname: Sidani fullname: Sidani, Charif organization: Department of Radiology, University of Miami, Miami, Florida, USA – sequence: 7 givenname: Manuel Lora surname: Gonzalez fullname: Gonzalez, Manuel Lora organization: Department of Pathology, Washington University, St. Louis, Missouri, USA – sequence: 8 givenname: Sabina surname: Casula fullname: Casula, Sabina organization: Department of Endocrinology, Miami Veterans Affairs Healthcare System, Miami, Florida, USA – sequence: 9 givenname: Atil Yilmaz surname: Kargi fullname: Kargi, Atil Yilmaz organization: Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32364010$$D View this record in MEDLINE/PubMed |
BookMark | eNo90FFPgzAQB_DGaNymPvpq-gU221IoPCLOSbJoovN5KXCFKrRLy6J8ML-f6NSnu1x--d_lZujYWAMIXVKyoCROrvtmWDBCkwWJRHCEpjQMxTwhQkzQzPtXQmgUi-AUTQIWRJxQMkWfaQdOl9LgTTM4qyucem9LLXttDX62xtZO7hpd4ift37A0I1DadRKvwABefuwceP9ts1aOjdLgcNqOd_1YPc5tV2hzyFPW4b4BfKtlbazXHlv1v_jBVvsWPH7XfYNvYHS-kjiTPdTWDTjPc5wNvW1tPZyjEyVbDxe_9Qy93C032f18_bjKs3Q9LwMR9XMFSUEV54wlXFDgPKpiSqRiUESkCMMQuKIiSKASksaj4WGlOCUMIIZAMnaGrg65u33RQbXdOd1JN2z__se-ANNNdR8 |
CitedBy_id | crossref_primary_10_1016_j_acra_2023_04_029 crossref_primary_10_1177_01945998211004155 crossref_primary_10_1089_thy_2022_0269 crossref_primary_10_3390_jcm13061759 crossref_primary_10_3390_endocrines2020009 crossref_primary_10_1089_ct_2021_33_269_273 crossref_primary_10_1016_j_prp_2023_154516 crossref_primary_10_3390_diagnostics12040944 crossref_primary_10_3389_fendo_2021_649522 |
ContentType | Journal Article |
DBID | NPM |
DOI | 10.1089/thy.2019.0673 |
DatabaseName | PubMed |
DatabaseTitle | PubMed |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1557-9077 |
ExternalDocumentID | 32364010 |
Genre | Journal Article |
GroupedDBID | --- 0R~ 1-M 123 29Q 34G 39C 4.4 53G 5RE AAQQT ABBKN ABJNI ABOCM ACGFO ACGFS ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BNQNF CAG COF CS3 DU5 EBS EJD EMOBN F5P IAO IER IHR IM4 INH INR ITC MV1 NPM NQHIM O9- P2P RIG RML RMSOB UDS UE5 |
ID | FETCH-LOGICAL-c376t-fe9b1f44229471e446d810af2eb60b555e4f1739ed7a1894745df4102ee8e3a22 |
IngestDate | Sat Sep 28 08:26:45 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | atypia of undetermined significance thyroid nodule GEC Bethesda ATA ultrasound |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c376t-fe9b1f44229471e446d810af2eb60b555e4f1739ed7a1894745df4102ee8e3a22 |
OpenAccessLink | https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?article=10890&context=open_access_pubs |
PMID | 32364010 |
ParticipantIDs | pubmed_primary_32364010 |
PublicationCentury | 2000 |
PublicationDate | 2020-11-00 |
PublicationDateYYYYMMDD | 2020-11-01 |
PublicationDate_xml | – month: 11 year: 2020 text: 2020-11-00 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Thyroid (New York, N.Y.) |
PublicationTitleAlternate | Thyroid |
PublicationYear | 2020 |
SSID | ssj0016873 |
Score | 2.4007053 |
Snippet | The Afirma gene expression classifier (GEC) has been used to aid in the diagnosis and management of thyroid nodules having Bethesda category III fine-needle... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 1613 |
Title | American Thyroid Association Sonographic Risk and Afirma Gene Expression Classifier Alone and in Combination for the Diagnosis of Thyroid Nodules with Bethesda Category III Cytology |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32364010 |
Volume | 30 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1bb9MwFICtDqRpL4j7HZ0H3qaMJnFuj2WAVqT1AXVob5Nd21pom05b-lD-F7-Lv8A5sZ2kU0HASxTFSWPlfD22z82MvdURN1LKWRDHKg64MqgHcWAL0kJlkcnCYqbIo3s6SU_O-Ofz5Hww-NmLWlrX8mj2fWdeyf9IFa-hXClL9h8k2_4oXsBzlC8eUcJ4_CsZt-6W6eXmelWq_semIBhbjppC5SmAnEzkI1NS8hEVm6YqxzYItrJbY5aGMk9Gi1XlXAqUD7jElfN2POIHG5xn65j4F09War3QLlXuPSUR3yhB6YVNBszheDw-PN7UnQn_m4fUPr5jS6C-iQJHcrJiCpdcVC42XfjwpZ7P18u5qGtrzR5Va9_2VdAW5Ndi2T4oyAZBGVedB8tFlXxZ32xZQHC5G7YWEO20dpIFuMrP-mrduXscvmFPSeMkN945egxzKr6KfxAK-SuOaA-f_n0o_Ktlg1JMZfeHNh73z623inn7pj22l-WkkCdkXHJOrzTPYlcGFnvybqsfB2zfP3trAdRMhKb32T23goGRxfEBG-jqIds_dTEaj9gPTyU46UKPSuhRCUQlIGlgqQSiEjoqoaMSGiqbe0u83lEJSCUgbdBSCSvTvthRCUQleCrBUwlIJXgqH7OzTx-nxyeB2xwkmOGYWAdGFzI0nEdRgfMrzXmq8nAoTKRlOpRJkmhuwiwutMpEmOM9PFGG43Ra61zHIoqesDsVdv0ZA5EaXkgT8wKX50mYy4QL1FFZkTdu_OQ5e2o_-MWVrQBz4UXx4rctL9lBh-ordtegytGvcf5ayzeN1H8BLImgyw |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=American+Thyroid+Association+Sonographic+Risk+and+Afirma+Gene+Expression+Classifier+Alone+and+in+Combination+for+the+Diagnosis+of+Thyroid+Nodules+with+Bethesda+Category+III+Cytology&rft.jtitle=Thyroid+%28New+York%2C+N.Y.%29&rft.au=Arosemena%2C+Marilyn&rft.au=Thekkumkattil%2C+Anu&rft.au=Valderrama%2C+Maria+Linares&rft.au=Kuker%2C+Russ&rft.date=2020-11-01&rft.eissn=1557-9077&rft.volume=30&rft.issue=11&rft.spage=1613&rft_id=info:doi/10.1089%2Fthy.2019.0673&rft_id=info%3Apmid%2F32364010&rft_id=info%3Apmid%2F32364010&rft.externalDocID=32364010 |